Clinical and Dermoscopic Evaluation of the Effectiveness of Metformin versus Pioglitazone in Acanthosis Nigricans: A Randomised Controlled Trial
Abstract
Background: Acanthosis nigricans (AN) features thick, hyperpigmented skin in flexural areas, often indicating insulin resistance. Dermoscopy of AN demonstrates sulci cutis and crista cutis, and differentiates it from other pigmentary dermatoses. Comparative efficacy studies are lacking in the literature. This study evaluates the clinical and dermoscopic changes in AN treated with metformin and pioglitazone.
Patients and methods: A randomised open-label trial was conducted on consenting AN patients aged 18 years or older. Patients were randomized to receive either metformin 500mg twice a day or pioglitazone 7.5mg twice a day for 3 months. Clinical grading, anthropometric measurements, and dermoscopic features were compared at baseline and at study completion at 12 weeks using IBM SPSS v26.
Results: Sixty-five patients (mean age 35 years) were distributed between two groups. Both drugs significantly improved clinical grading from baseline to 12 weeks. Metformin notably reduced the body mass index (29.55 ± 3.51 kg/m 2 to 28.92 ± 3.44 kg/m 2 ) and weight (76.58 ± 10.21 kg to 74.64 ± 10.30 kg) more than pioglitazone, but there were no significant differences in other parameters. Both drugs significantly changed dermoscopic parameters, including sulci cutis and hyperpigmented dots and globules, with no differences between them. Papillary projection morphology correlated significantly with clinical grading.
Limitations: The limitations of this study include a relatively short study…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.